Alaunos Therapeutics, Inc.TCRTEarnings & Financial Report
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
TCRT Q4 FY2025 Key Financial Metrics
Revenue
$3.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-40.0%
Alaunos Therapeutics, Inc. Q4 FY2025 Financial Summary
Alaunos Therapeutics, Inc. reported revenue of $3.0K (down 40.0% YoY) for Q4 FY2025, with a net profit of N/A (down 20.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $3.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Alaunos Therapeutics, Inc. Annual Revenue by Year
Alaunos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.0K).
Alaunos Therapeutics, Inc. Quarterly Revenue & Net Profit History
Alaunos Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.0K | -40.0% | N/A | N/A |
| Q3 FY2025 | $0 | — | $-1.2M | N/A |
| Q2 FY2025 | $0 | — | $-1.1M | N/A |
| Q1 FY2025 | $2.0K | +100.0% | $-1.1M | -53650.0% |
| Q4 FY2024 | $5.0K | +400.0% | N/A | N/A |
| Q3 FY2024 | $0 | — | $-1.1M | N/A |
| Q2 FY2024 | $4.0K | +0.0% | $-1.1M | -28225.0% |
| Q1 FY2024 | $1.0K | — | $-1.7M | -168200.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1000 | $4000 | $0 | $5000 | $2000 | $0 | $0 | $3000 |
| YoY Growth | N/A | 0.0% | N/A | 400.0% | 100.0% | N/A | N/A | -40.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.0M | $4.7M | $3.5M | $2.8M | $2.1M | $4.7M | $3.7M | $3.0M |
| Liabilities | $1.2M | $907000 | $826000 | $692000 | $1.1M | $1.1M | $921000 | $813000 |
| Equity | $4.8M | $3.8M | $2.7M | $2.1M | $1.1M | $3.7M | $2.8M | $2.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.7M | $-781000 | $-5.0M | $-772000 | $-701000 | $-844000 | $-2.9M |